PortfoliosLab logoPortfoliosLab logo
ABUS vs. ARMP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ABUS vs. ARMP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ABUS achieves a -9.77% return, which is significantly higher than ARMP's -27.71% return. Over the past 10 years, ABUS has outperformed ARMP with an annualized return of 0.57%, while ARMP has yielded a comparatively lower -30.31% annualized return.


ABUS

1D
-1.59%
1M
-10.88%
6M
5.08%
YTD
-9.77%
1Y
32.72%
3Y*
25.80%
5Y*
10.04%
10Y*
0.57%
ALL TIME*
-7.94%

ARMP

1D
-5.02%
1M
-22.92%
6M
-32.24%
YTD
-27.71%
1Y
78.74%
3Y*
21.04%
5Y*
3.46%
10Y*
-30.31%
ALL TIME*
-32.73%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$5.92M$9.50M$8.90M
$728.24K$797.82K$910.24K

ABUS vs. ARMP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ABUS
Arbutus Biopharma Corporation
-9.77%47.09%30.80%7.30%-40.10%9.58%27.70%-27.42%-24.16%106.12%
ARMP
Armata Pharmaceuticals Inc.
-27.71%239.46%-42.90%161.29%-77.37%83.59%-8.16%12.53%-79.57%-77.05%

Correlation

The correlation between ABUS and ARMP is 0.10, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.10

Correlation (3Y)
Balances recent behavior with more history.

0.11

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.07

Correlation (10Y)
Provides a long-term view across more market conditions.

0.04

Correlation (All Time)
Calculated using the full available price history since Aug 3, 2015

0.06

Fundamentals

Market Cap

ABUS:

$857.31M

ARMP:

$166.67M

EPS

ABUS:

$0.83

ARMP:

-$7.78

PS Ratio

ABUS:

4.37

ARMP:

37.38

Total Revenue (TTM)

ABUS:

$191.45M

ARMP:

$4.41M

Gross Profit (TTM)

ABUS:

$12.30M

ARMP:

$3.26M

EBITDA (TTM)

ABUS:

$156.13M

ARMP:

-$27.14M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Arbutus Biopharma Corporation

Armata Pharmaceuticals Inc.

Often compared with ABUS:
ABUS vs. QTUMABUS vs. ALNY
Often compared with ARMP:
ARMP vs. LXRXARMP vs. SGHT

Return for Risk

ABUS vs. ARMP — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ABUS
ABUS Risk / Return Rank: 6767
Overall Rank
ABUS Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
ABUS Sortino Ratio Rank: 6363
Sortino Ratio Rank
ABUS Omega Ratio Rank: 6262
Omega Ratio Rank
ABUS Calmar Ratio Rank: 7171
Calmar Ratio Rank
ABUS Martin Ratio Rank: 7171
Martin Ratio Rank

ARMP
ARMP Risk / Return Rank: 7373
Overall Rank
ARMP Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
ARMP Sortino Ratio Rank: 8383
Sortino Ratio Rank
ARMP Omega Ratio Rank: 7979
Omega Ratio Rank
ARMP Calmar Ratio Rank: 6969
Calmar Ratio Rank
ARMP Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ABUS vs. ARMP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Armata Pharmaceuticals Inc. (ARMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ABUSARMPDifference
Sharpe ratioReturn per unit of total volatility

+0.11

Sortino ratioReturn per unit of downside risk

-1.02

Omega ratioGain probability vs. loss probability

1.15

1.26

-0.11

Calmar ratioReturn relative to maximum drawdown

1.26

1.15

+0.11

Martin ratioReturn relative to average drawdown

3.04

2.83

+0.20

ABUS vs. ARMP - Sharpe Ratio Comparison

The current ABUS Sharpe Ratio is 0.69, which is comparable to the ARMP Sharpe Ratio of 0.58. The chart below compares the historical Sharpe Ratios of ABUS and ARMP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ABUS vs. ARMP - Drawdown Comparison

The maximum ABUS drawdown since its inception was -92.96%, smaller than the maximum ARMP drawdown of -99.98%. Use the drawdown chart below to compare losses from any high point for ABUS and ARMP.


Loading charts...

Drawdown Indicators


ABUSARMPDifference

Max Drawdown

Largest peak-to-trough decline

-92.96%

-99.98%

+7.02%

Max Drawdown (1Y)

Largest decline over 1 year

-25.86%

-74.59%

+48.73%

Max Drawdown (3Y)

Largest decline over 3 years

-36.84%

-79.22%

+42.38%

Max Drawdown (5Y)

Largest decline over 5 years

-63.42%

-85.70%

+22.28%

Max Drawdown (10Y)

Largest decline over 10 years

-92.96%

-99.68%

+6.72%

Current Drawdown

Current decline from peak

-64.86%

-99.91%

+35.05%

Average Drawdown

Average peak-to-trough decline

-68.97%

-82.94%

+13.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

10.66%

30.19%

-19.53%

Volatility

ABUS vs. ARMP - Volatility Comparison

The current volatility for Arbutus Biopharma Corporation (ABUS) is 13.94%, while Armata Pharmaceuticals Inc. (ARMP) has a volatility of 34.90%. This indicates that ABUS experiences smaller price fluctuations and is considered to be less risky than ARMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ABUSARMPDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.94%

34.90%

-20.96%

Volatility (6M)

Calculated over the trailing 6-month period

32.09%

77.31%

-45.22%

Volatility (1Y)

Calculated over the trailing 1-year period

47.05%

146.68%

-99.63%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.45%

115.17%

-60.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

85.41%

110.94%

-25.53%

Dividends

ABUS vs. ARMP - Dividend Comparison

Neither ABUS nor ARMP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ABUS vs. ARMP - Financials Comparison

This section allows you to compare key financial metrics between Arbutus Biopharma Corporation and Armata Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


ABUS and ARMP have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARMP has higher volatility (34.90%) compared to ABUS (13.94%). In terms of maximum drawdown, ABUS dropped -92.96% vs ARMP's -99.98%.

ABUS currently has the higher Sharpe Ratio (0.69 vs 0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ABUS and ARMP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer